Lee Hemin, Tedeschi Sara K, Chen Sarah K, Monach Paul A, Kim Erin, Liu Jun, Pethoe-Schramm Attila, Yau Vincent, Kim Seoyoung C
Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Brigham and Women's Hospital, Harvard Medical School, and US Department of Veterans Affairs Boston Healthcare System, Boston, Massachusetts.
ACR Open Rheumatol. 2021 Feb;3(2):72-78. doi: 10.1002/acr2.11218. Epub 2021 Jan 25.
The objective of this study was to validate claims-based algorithms for identifying acute giant cell arteritis (GCA) that will help generate real-world evidence on comparative effectiveness research and epidemiologic studies. Among patients identified by the GCA algorithm, we further investigated whether GCA flares could be detected by using claims data.
We developed five claims-based algorithms based on a combination of International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes, specialist visits, and dispensed medications using Medicare Parts A, B, and D linked to electronic medical records (2006-2014). Acute cases of GCA were determined by chart review using the treating physician's diagnosis of GCA as the gold standard. Among the patients identified with acute GCA, we assessed if a GCA flare occurred during the year after initial diagnosis.
The number of patients identified by each algorithm ranged from 220 to 896. Positive predictive values (PPVs) of the algorithms ranged from 60.7% to 84.8%. Requirement for disease-specific workups, multiple diagnosis codes, or specialist visits improved the PPVs. The highest PPV (84.8%) was noted in an algorithm that required two or more diagnosis codes of GCA from inpatient, emergency department, or outpatient rheumatology visits plus a prednisone-equivalent dose greater than or equal to 40 mg/day occurring 14 days before or after the second ICD-9 diagnosis date, with the cumulative days' supply greater than or equal to 14 days. Among patients identified as having GCA, 18.2% of patients had definite evidence of a flare and 25% had a potential flare.
A claims-based algorithm requiring two or more ICD-9 diagnosis codes from inpatient, emergency department, or outpatient rheumatology visits and high-dose glucocorticoid dispensing can be a useful tool to identify acute GCA cases in large administrative claims databases.
本研究的目的是验证用于识别急性巨细胞动脉炎(GCA)的基于索赔的算法,这将有助于生成关于比较有效性研究和流行病学研究的真实世界证据。在通过GCA算法识别出的患者中,我们进一步研究了是否可以使用索赔数据检测到GCA复发。
我们基于国际疾病分类第九版(ICD-9)诊断代码、专科就诊以及使用与电子病历相关联的医疗保险A、B和D部分中的配药情况,开发了五种基于索赔的算法(2006 - 2014年)。GCA的急性病例通过病历审查确定,以治疗医生对GCA的诊断作为金标准。在确诊为急性GCA的患者中,我们评估了初次诊断后一年内是否发生GCA复发。
每种算法识别出的患者数量在220至896之间。算法的阳性预测值(PPV)在60.7%至84.8%之间。对特定疾病检查、多个诊断代码或专科就诊的要求提高了PPV。在一种算法中观察到最高的PPV(84.8%),该算法要求来自住院、急诊科或门诊风湿病就诊的两个或更多GCA诊断代码,加上在第二个ICD - 9诊断日期之前或之后14天内出现的泼尼松等效剂量大于或等于40毫克/天,且累计供应天数大于或等于14天。在被确定患有GCA的患者中,18.2%的患者有明确的复发证据,25%的患者有潜在复发。
一种基于索赔的算法,要求来自住院、急诊科或门诊风湿病就诊的两个或更多ICD - 9诊断代码以及高剂量糖皮质激素配药,可作为在大型行政索赔数据库中识别急性GCA病例的有用工具。